Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 1
1954 1
1955 2
1956 1
1958 1
1959 1
1965 2
1966 3
1967 3
1968 7
1969 10
1970 9
1971 15
1972 6
1973 17
1974 13
1975 18
1976 14
1977 11
1978 10
1979 13
1980 8
1981 16
1982 13
1983 18
1984 24
1985 32
1986 33
1987 31
1988 30
1989 42
1990 42
1991 48
1992 46
1993 43
1994 67
1995 73
1996 71
1997 78
1998 64
1999 70
2000 72
2001 82
2002 99
2003 94
2004 77
2005 92
2006 106
2007 97
2008 136
2009 134
2010 143
2011 162
2012 211
2013 194
2014 179
2015 187
2016 230
2017 245
2018 311
2019 295
2020 325
2021 317
2022 320
2023 311
2024 109

Text availability

Article attribute

Article type

Publication date

Search Results

4,928 results

Results by year

Filters applied: . Clear all
Page 1
New Treatment Paradigms in Primary Biliary Cholangitis.
Levy C, Manns M, Hirschfield G. Levy C, et al. Clin Gastroenterol Hepatol. 2023 Jul;21(8):2076-2087. doi: 10.1016/j.cgh.2023.02.005. Epub 2023 Feb 19. Clin Gastroenterol Hepatol. 2023. PMID: 36809835 Free article. Review.
Primary biliary cholangitis (PBC) is an archetypal autoimmune disease. Chronic lymphocytic cholangitis is associated with interface hepatitis, ductopenia, cholestasis, and progressive biliary fibrosis. ...Future PBC licensed therapy will likely include peroxisome pr …
Primary biliary cholangitis (PBC) is an archetypal autoimmune disease. Chronic lymphocytic cholangitis is associated with inte …
Primary biliary cholangitis.
Lleo A, Wang GQ, Gershwin ME, Hirschfield GM. Lleo A, et al. Lancet. 2020 Dec 12;396(10266):1915-1926. doi: 10.1016/S0140-6736(20)31607-X. Lancet. 2020. PMID: 33308474 Review.
Primary biliary cholangitis is an autoimmune liver disease that predominantly affects women. ...Off-label therapy is recognised as an alternative, notably with the pan-PPAR agonist bezafibrate; clinical trial agents are also under development. Baseline charac …
Primary biliary cholangitis is an autoimmune liver disease that predominantly affects women. ...Off-label therapy is recognised as an …
Toward personalized immunotherapy in sepsis: The PROVIDE randomized clinical trial.
Leventogiannis K, Kyriazopoulou E, Antonakos N, Kotsaki A, Tsangaris I, Markopoulou D, Grondman I, Rovina N, Theodorou V, Antoniadou E, Koutsodimitropoulos I, Dalekos G, Vlachogianni G, Akinosoglou K, Koulouras V, Komnos A, Kontopoulou T, Prekates A, Koutsoukou A, van der Meer JWM, Dimopoulos G, Kyprianou M, Netea MG, Giamarellos-Bourboulis EJ. Leventogiannis K, et al. Cell Rep Med. 2022 Nov 15;3(11):100817. doi: 10.1016/j.xcrm.2022.100817. Cell Rep Med. 2022. PMID: 36384100 Free PMC article. Clinical Trial.
The state of immune activation may guide targeted immunotherapy in sepsis. In a double-blind, double-dummy randomized clinical study, 240 patients with sepsis due to lung infection, bacteremia, or acute cholangitis were subjected to measurements of serum ferr …
The state of immune activation may guide targeted immunotherapy in sepsis. In a double-blind, double-dummy randomized clinical …
Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence.
Cheng HS, Tan WR, Low ZS, Marvalim C, Lee JYH, Tan NS. Cheng HS, et al. Int J Mol Sci. 2019 Oct 11;20(20):5055. doi: 10.3390/ijms20205055. Int J Mol Sci. 2019. PMID: 31614690 Free PMC article. Review.
In this review we aim to consolidate existing clinical evidence of PPAR modulators, highlighting their clinical prospects and challenges. Findings from clinical trials revealed that different agonists of the same PPAR subtype could present different safety pr …
In this review we aim to consolidate existing clinical evidence of PPAR modulators, highlighting their clinical prospects and …
A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA.
Schattenberg JM, Pares A, Kowdley KV, Heneghan MA, Caldwell S, Pratt D, Bonder A, Hirschfield GM, Levy C, Vierling J, Jones D, Tailleux A, Staels B, Megnien S, Hanf R, Magrez D, Birman P, Luketic V. Schattenberg JM, et al. J Hepatol. 2021 Jun;74(6):1344-1354. doi: 10.1016/j.jhep.2021.01.013. Epub 2021 Jan 21. J Hepatol. 2021. PMID: 33484775 Free article. Clinical Trial.
Elafibranor is a nuclear receptor agonist that we tested in a randomized clinical trial over 12 weeks. It successfully decreased levels of disease activity markers, including alkaline phosphatase. Thus, this study is the foundation for a larger prospective st …
Elafibranor is a nuclear receptor agonist that we tested in a randomized clinical trial over 12 weeks. It successfully …
A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis.
Corpechot C, Chazouillères O, Rousseau A, Le Gruyer A, Habersetzer F, Mathurin P, Goria O, Potier P, Minello A, Silvain C, Abergel A, Debette-Gratien M, Larrey D, Roux O, Bronowicki JP, Boursier J, de Ledinghen V, Heurgue-Berlot A, Nguyen-Khac E, Zoulim F, Ollivier-Hourmand I, Zarski JP, Nkontchou G, Lemoinne S, Humbert L, Rainteau D, Lefèvre G, de Chaisemartin L, Chollet-Martin S, Gaouar F, Admane FH, Simon T, Poupon R. Corpechot C, et al. N Engl J Med. 2018 Jun 7;378(23):2171-2181. doi: 10.1056/NEJMoa1714519. N Engl J Med. 2018. PMID: 29874528 Free article. Clinical Trial.
BACKGROUND: Patients with primary biliary cholangitis who have an inadequate response to therapy with ursodeoxycholic acid are at high risk for disease progression. ...METHODS: In this 24-month, double-blind, placebo-controlled, phase 3 trial, we randomly ass …
BACKGROUND: Patients with primary biliary cholangitis who have an inadequate response to therapy with ursodeoxycholic acid are at hig …
The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines.
Hirschfield GM, Dyson JK, Alexander GJM, Chapman MH, Collier J, Hübscher S, Patanwala I, Pereira SP, Thain C, Thorburn D, Tiniakos D, Walmsley M, Webster G, Jones DEJ. Hirschfield GM, et al. Gut. 2018 Sep;67(9):1568-1594. doi: 10.1136/gutjnl-2017-315259. Epub 2018 Mar 28. Gut. 2018. PMID: 29593060 Free PMC article.
Primary biliary cholangitis (formerly known as primary biliary cirrhosis, PBC) is an autoimmune liver disease in which a cycle of immune mediated biliary epithelial cell injury, cholestasis and progressive fibrosis can culminate over time in an end-stage biliary cirrhosis. …
Primary biliary cholangitis (formerly known as primary biliary cirrhosis, PBC) is an autoimmune liver disease in which a cycle of imm …
Conventional vs Short Duration of Antibiotics in Patients With Moderate or Severe Cholangitis: Noninferiority Randomized Trial.
Srinu D, Shah J, Jena A, Jearth V, Singh AK, Mandavdhare HS, Sharma V, Irrinki S, Sakaray YR, Gupta R, Gautam V, Rana S, Dutta U. Srinu D, et al. Am J Gastroenterol. 2024 Jan 1;119(1):176-182. doi: 10.14309/ajg.0000000000002499. Epub 2023 Sep 21. Am J Gastroenterol. 2024. PMID: 37732816 Clinical Trial.
We conducted a single-center, randomized, noninferiority trial to compare short duration of antibiotic therapy with conventional duration of antibiotic therapy in patients with moderate or severe cholangitis. ...The primary outcome was clinical cure (a …
We conducted a single-center, randomized, noninferiority trial to compare short duration of antibiotic therapy with convention …
Primary Biliary Cholangitis and Primary Sclerosing Cholangitis.
Yokoda RT, Carey EJ. Yokoda RT, et al. Am J Gastroenterol. 2019 Oct;114(10):1593-1605. doi: 10.14309/ajg.0000000000000268. Am J Gastroenterol. 2019. PMID: 31169523 Review.
Cholestatic liver diseases encompass a broad spectrum of pathologies, with the core injury occurring at the level of cholangiocytes and progressing to hepatic fibrosis and liver dysfunction. Primary biliary cholangitis and primary sclerosing cholangitis are the most …
Cholestatic liver diseases encompass a broad spectrum of pathologies, with the core injury occurring at the level of cholangiocytes and prog …
Cholangiocyte-Derived Exosomal Long Noncoding RNA H19 Promotes Hepatic Stellate Cell Activation and Cholestatic Liver Fibrosis.
Liu R, Li X, Zhu W, Wang Y, Zhao D, Wang X, Gurley EC, Liang G, Chen W, Lai G, Pandak WM, Robert Lippman H, Bajaj JS, Hylemon PB, Zhou H. Liu R, et al. Hepatology. 2019 Oct;70(4):1317-1335. doi: 10.1002/hep.30662. Epub 2019 May 24. Hepatology. 2019. PMID: 30985008 Free PMC article.
Collagen gel contraction and bromodeoxyuridine assays were used to determine the effect of exosomal-H19 on HSC activation and proliferation. Mouse and human primary sclerosing cholangitis (PSC)/primary biliary cholangitis (PBC) liver samples were analyzed by real-ti …
Collagen gel contraction and bromodeoxyuridine assays were used to determine the effect of exosomal-H19 on HSC activation and proliferation. …
4,928 results